* Announced on Sunday Phase 3 trial results of CABOMETYX
(cabozantinib) tablets demonstrating significant overall
survival benefit for previously treated patients with advanced
renal cell carcinoma presented at ASCO
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
No comments:
Post a Comment